Read this manager's filing book
Disclosed positions
Velan Capital Investment Management LP: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- PRAXIS PRECISION MEDICINES I
- Ticker
- PRAX
- Class
- COM NEW
- Reported value
- $29,722,991
- Reported amount
- 88,781
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001848809-26-000003Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Show the table · 50 rows, 7 columns
Scroll sideways to compare all columns. Select a heading to sort.
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $29,722,991 | 88,781 | SH | None |
| MAPLIGHT THERAPEUTICS INC | MPLT | COM | $17,665,285 | 492,893 | SH | None |
| SUTRO BIOPHARMA INC | STRO | COM SHS | $17,003,712 | 512,160 | SH | None |
| IMMIX BIOPHARMA INC | IMMX | COM | $11,186,350 | 1,085,000 | SH | None |
| PROTARA THERAPEUTICS INC | TARA | COM STK | $10,866,571 | 2,844,652 | SH | None |
| ABIVAX SA | ABVX | SPONSORED ADS | $8,745,854 | 65,630 | SH | None |
| TENAX THERAPEUTICS INC | TENX | COM NEW | $8,002,282 | 549,985 | SH | None |
| ANTERIS TECHNOLOGIES GLOBAL | AVR | COM | $6,895,000 | 700,000 | SH | None |
| EDESA BIOTECH INC | EDSA | COM NEW | $6,727,575 | 827,500 | SH | None |
| EVOMMUNE INC | EVMN | COM SHS | $5,997,179 | 451,255 | SH | None |
| AVALO THERAPEUTICS INC | AVTX | COM NEW | $5,995,873 | 324,452 | SH | None |
| XENCOR INC | XNCR | COM | $4,105,500 | 255,000 | SH | None |
| REZOLUTE INC | RZLT | COM NEW | $3,900,000 | 750,000 | SH | None |
| HERON THERAPEUTICS INC | HRTX | COM | $3,735,904 | 8,753,290 | SH | None |
| VERRICA PHARMACEUTICALS INC | VRCA | COM SHS | $2,885,941 | 471,559 | SH | None |
| C4 THERAPEUTICS INC | CCCC | COM STK | $2,661,900 | 570,000 | SH | None |
| EUPRAXIA PHARMACEUTICALS INC | EPRX | COM | $2,326,720 | 352,000 | SH | None |
| ADMA BIOLOGICS INC | ADMA | COM | $2,092,500 | 250,000 | SH | None |
| REIN THERAPEUTICS INC | RNTX | COM NEW | $1,768,000 | 1,700,000 | SH | None |
| LYELL IMMUNOPHARMA INC | LYEL | COM NEW | $1,475,250 | 105,000 | SH | None |
| NASUS PHARMA LTD | Unresolved | ORD SHS | $1,257,865 | 359,390 | SH | None |
| PROFOUND MED CORP | PROF | COM NEW | $1,132,349 | 170,278 | SH | None |
| JASPER THERAPEUTICS INC | JSPR | COM NEW | $1,123,394 | 2,668,395 | SH | None |
| TENAX THERAPEUTICS INC | TENX | COM NEW | $999,585 | 68,700 | SH | Call |
| PROTAGONIST THERAPEUTICS INC | PTGX | COM | $453,546 | 3,700 | SH | None |
| CYTOMX THERAPEUTICS INC. | CTMX | COM | $450,000 | 120,000 | SH | None |
| NEUMORA THERAPEUTICS INC. | NMRA | COM | $391,000 | 230,000 | SH | None |
| NURIX THERAPEUTICS INC | NRIX | COM | $388,160 | 16,000 | SH | None |
| OVID THERAPEUTICS INC | OVID | COM | $349,700 | 130,000 | SH | None |
| PRECISION BIOSCIENCES INC | DTIL | COM NEW | $314,400 | 40,000 | SH | None |
| MINERALYS THERAPEUTICS INC | MLYS | COM | $296,780 | 11,000 | SH | None |
| MACROGENICS INC | MGNX | COM | $277,200 | 60,000 | SH | None |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | COM NEW | $243,880 | 26,000 | SH | None |
| ARTIVA BIOTHERAPEUTICS INC | ARTV | COM | $242,500 | 25,000 | SH | None |
| REPLIMUNE GROUP INC | REPL | COM | $221,400 | 20,000 | SH | None |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $218,600 | 10,000 | SH | None |
| IMMUNOME INC | IMNM | COM | $211,900 | 10,000 | SH | None |
| TECTONIC THERAPEUTIC INC | TECX | COM | $206,250 | 6,000 | SH | None |
| ROCKET PHARMACEUTICALS INC | RCKT | COM | $205,200 | 60,000 | SH | None |
| KARYOPHARM THERAPEUTICS INC | KPTI | COM NEW | $195,400 | 20,000 | SH | None |
| AN2 THERAPEUTICS INC | ANTX | COM | $193,600 | 40,000 | SH | None |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $183,700 | 10,000 | SH | None |
| SCYNEXIS INC | SCYX | COM | $162,800 | 40,000 | SH | None |
| QUOIN PHARMACEUTICALS LTD | QNRX | SPONSORED ADS | $156,680 | 32,372 | SH | None |
| XILIO THERAPEUTICS INC | XLO | COM | $136,850 | 14,285 | SH | None |
| INSPIREMD INC | NSPR | COM | $103,711 | 148,138 | SH | None |
| KALARIS THERAPEUTICS INC | KLRS | COM | $101,750 | 25,000 | SH | None |
| LARIMAR THERAPEUTICS INC | LRMR | COM | $100,650 | 33,000 | SH | None |
| PROQR THRAPEUTICS N V | PRQR | SHS EURO | $83,700 | 45,000 | SH | None |
| CONTEXT THERAPEUTICS INC | CNTX | COM | $33,068 | 59,700 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 1 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.